A Pan-TB Regimen Targeting Host and Microbe

Summary

This project will develop the first regimen meeting WHO criteria for a pan-TB indication, ie, not requiring knowledge of RIF susceptibility. The regimen will test sutezolid at 2 dose levels, with the approved anti-TB drugs bedaquiline and pretomanid, in a phase 2c trial. It will also test whether the addition of N-acetylcysteine (NAC), a re-purposed host-directed WHO essential medicine, can protect the lung and liver against oxidative damage, preserve lung function, and accelerate the eradication of MTB infection by replenishing glutathione (GSH).

Timeline

Start

2023-07-28

Primary completion

2026-01

Completion

2026-01

Publications

• Mudzengi D, Mashatole S, Xiang Q, Adrion C, Glover N, Ngwanto T, Mdluli J, Boniface S, Rassool M, Matome B, Paramo L, Svensson E, Fasanmi A, Angelo S, Moyo M, Marx C, Khosa C, Mokaba L, Mofokeng N, Lalashowi J, Nacy C, Charalambous S, Fumane E, Maphossa V, Beattie T, Brumskine W, Venter C, Mapamba D, Heinrich N, Rajaram S, Kooverjee S, Botha L, Nell M, Easton A, Foraida S, Warren RM, Sabi I, Ntinginya N, Wallis RS; panTB-HM Consortium. panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe. Trials. 2026 Feb 27;27(1):271. doi: 10.1186/s13063-026-09568-9.

Drugs

Indications